Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Drops Perampanel In Parkinson’s, Plans First Neuropathy Submission For 2010

This article was originally published in PharmAsia News

Executive Summary

Eisai announced April 11 it has abandoned development of its novel AMPA receptor antagonist perampanel in Parkinson's disease after a second Phase III trial failed, but the Tokyo firm is forging ahead with the compound in other neurological indications
Advertisement

Related Content

Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment
Eisai's Perampanel Shows Positive Phase III Results For Epilepsy Following Failure As Parkinson's Treatment
Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease
Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease
Advertisement
UsernamePublicRestriction

Register

SC068165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel